PT-141
Product Name:Bremelanotide,PT-141
Alias: Brmelanotice,BreMelanotide Acetate
CAS Registry Number: 189691-06-3
MF: C50H69N15O10
MW: 1040.17736
Appearance: White powder
Purity:99%
Grade: Pharmceutical Grade
Developed From Melanotan II
Bremelanotide or PT-141, a research chemical and peptide, belongs to the classification known as melanocyte stimulating hormones (MSH). It is a hexapeptide of alpha-MSH, and was originally developed from the MSH Melanotan II, a peptide agent that was reviewed in trials for sunless tanning but, unexpectedly, resulted in sexual arousal and sexual spontaneous erections in nine of ten test subjects.
Bremelanotide is a compound under drug as a treatment for female and male sexual dysfunction, hemorrhagic shock and reperfusion injury.
Treatment of Sexual Dysfunction
Bremelanotide or PT-141 is the generic term for a new research peptide for use in helping improve sexual dysfunction in men (erectile dysfunction or impotence) as well as helping improve sexual dysfunction in women (sexual arousal disorder).
PT-141 is a potential remedy for the treatment of sexual dysfunction; specifically, male erectile dysfunction.Bremelanotide, PT-141 does not act on the vascular system like the former compounds but it is known and has been shown to help increase sexual activity in both male and female mammals. Bremelanotide PT-141 allegedly works by activating melanocortin receptors in the brain, therefore helping increase ones sexual stimulation.
Bremelanotide is a novel treatment that could potentially change the face of treating sexual disorders, not only because of its effectiveness due to a unique mode of action, but also due to its safety and the fact it works synergistically with other ED/SAD treatments.
Bremelanotide is effective in its potential to treat sexual desire disorders as well as disorders that affect physical arousal. Bremelanotide induces lordosis in animal subjects, a sign of physical preparation for copulation. In males, it does not stimulate the vascular aspect of the penis, but instead acts to stimulate the central nervous system primarily via dopamine receptor activity to increase sexual desire and also demonstrates functionality in treating purely physical manifestations of ED/SAD, likely through improved signalling.
Co-administration of PT-141 and Sildenafil
Bremelanotide also offers potential as a low-dose concurrent treatment with low-dose sildenafil.
The erectile response induced by co-administration of PT-141 and sildenafil was significantly greater than the response elicited by administration of sildenafil alone. Co-administration of PT-141 and sildenafil was safe and well-tolerated and did not result in new adverse events or adverse events that were increased in frequency or severity compared with monotherapy. Co-administration of intranasal PT-141 and a phosphodiesterase type 5 inhibitor may constitute a treatment alternative for patients in whom higher doses of a single therapy are not effective or well tolerated.
